Seeing Is Believing
Currently out of the existing stock ratings of David Novak, 17 are a BUY (100%).
Analyst David Novak works at STIFEL with a stock forecast success ratio of 50% fulfilled within 228.5 days on average. Previously, David Novak worked at RAYMOND JAMES.
David Novak’s has documented 31 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ZYME, Zymeworks . Common Stock at 10-Dec-2021.
Analyst best performing recommendations are on ZYME (ZYMEWORKS . COMMON STOCK).
The best stock recommendation documented was for ZYME (ZYMEWORKS . COMMON STOCK) at 10/1/2019. The price target of $40 was fulfilled within 52 days with a profit of $14.91 (59.43%) receiving and performance score of 11.43.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
3
$-4.67 (-60.89%)
4
1 years 11 months 26 days ago
2/5 (40%)
$1.92 (177.78%)
220
Hold
2 years 4 months 12 days ago
0/1 (0%)
$10.5 (123.53%)
Buy
24
$23.52 (4900.00%)
5 years 2 months 24 days ago
0/1 (0%)
$18.19 (313.08%)
What Year was the first public recommendation made by David Novak?